5-HTP and L-Theanine: The Calm-Focus Pair Explained

By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs

Summary

5-HTP is the direct biosynthetic precursor to serotonin, decarboxylated by aromatic L-amino acid decarboxylase, and roughly 70 percent of an oral dose reaches circulation (Birdsall, 1998). L-theanine modulates GABA, glutamate and dopamine, and a single 200 mg dose raises frontal alpha EEG power within hours (Williams et al., 2021; Nobre et al., 2008). The pairing is mechanistically coherent — one supplies serotonin substrate, the other shifts cortical state toward calm focus — but no published human RCT tests the specific 5-HTP plus L-theanine combination. The MIHIYO Labs Mood-Boost oral dissolving strip (ODS) is formulated around this calm-focus rationale, with honest limits acknowledged.

Why pair 5-HTP with L-theanine in the first place?

The direct answer: the two molecules act on different parts of the same problem. 5-HTP supplies the immediate biochemical substrate the brain needs to make serotonin, the neurotransmitter most associated with mood regulation. L-theanine does not change substrate at all — it changes cortical state, shifting brain activity toward the calmer alpha-wave pattern seen during relaxed-but-alert attention. One is a substrate; the other is a state modulator. The pairing is coherent on mechanism alone, even though the published human evidence for the specific combination is thinner than I would like.

This article walks through what each molecule actually does, what the clinical trials show, and where the evidence stops — because anyone selling you this stack as a sure-fire lift is overselling the data.

How does 5-HTP make serotonin in the brain?

5-HTP, formally 5-hydroxytryptophan, is the metabolic intermediate between the dietary amino acid L-tryptophan and serotonin (5-hydroxytryptamine, 5-HT). The biosynthetic pathway is short and well characterized.

In the brain, tryptophan is first converted to 5-HTP by the enzyme tryptophan hydroxylase (TPH). This is the rate-limiting step of serotonin synthesis — TPH is slow, easily inhibited, and competes with several other pathways for tryptophan (Nakamura & Hasegawa, 2009, IJTR). 5-HTP is then rapidly converted to serotonin by aromatic L-amino acid decarboxylase (AADC, also called dopa decarboxylase), a vitamin B6-dependent enzyme present in both neural tissue and the periphery.

Supplemental 5-HTP bypasses the slow TPH step entirely. Once absorbed, it crosses the blood-brain barrier — unlike serotonin itself, which does not — and is decarboxylated directly to serotonin (Birdsall, 1998, Altern Med Rev). The pharmacology is straightforward: feed the system its rate-limited intermediate, and serotonin synthesis rises wherever AADC is active.

Oral absorption is good. Birdsall's 1998 clinical review reports that approximately 70 percent of an oral 5-HTP dose reaches circulation. The standard supplement source is the seed of Griffonia simplicifolia, an African plant that accumulates 5-HTP at unusually high concentrations.

How does L-theanine work — and what does "alpha waves" actually mean?

L-theanine is N-ethyl-L-glutamine, an amino acid found in tea (Camellia sinensis) at roughly 1–2 percent of dry leaf weight. Structurally it is a glutamine analogue, which is the entry point for its central effects.

The neuropharmacology, summarized in Nathan et al.'s 2006 review (Journal of Herbal Pharmacotherapy, PMID 17182482) and extended by Türközü & Şanlier (2017) and Sumi et al. (2025, Sci Rep): L-theanine has affinity for AMPA, kainate, and NMDA glutamate receptors at micromolar concentrations; it inhibits glutamine uptake into neurons, likely through competition at the ASCT2 transporter; it directly activates GABA-A receptors; and it modulates brain serotonin, dopamine, and GABA levels. The net effect is a shift in the brain's excitatory-inhibitory balance toward inhibition, without sedation.

That shift shows up on EEG as increased alpha-wave power. Alpha waves (8–13 Hz) dominate cortical activity during relaxed wakefulness — eyes closed, awake, not actively concentrating on an external task. A 2008 randomized crossover study by Nobre et al. (Asia Pac J Clin Nutr, PMID 18296328) found that 50 and 200 mg of L-theanine significantly increased alpha activity in the posterior brain regions of healthy adults compared to placebo, with the effect emerging 45–105 minutes after dosing. A 2021 triple-blind crossover by Williams et al. (Neurol Ther, PMC8475422) confirmed the effect: a single 200 mg dose of AlphaWave L-theanine significantly increased frontal alpha power on EEG at three hours post-dose compared to placebo, in a healthy adult population.

L-theanine is not a sedative. The signature is "alert relaxation" — stress and sympathetic arousal blunted, attention preserved.

What the studies actually show for each molecule

Here is the most useful comparison: the targets, the typical study doses, and the highest-quality evidence available for each.

Two evidence threads deserve unpacking.

For 5-HTP, the Cochrane Database systematic review by Shaw, Turner & Del Mar (2002, PMID 11687048) screened 108 trials of 5-HTP and L-tryptophan for depression and found only two suitable for meta-analysis. Pooled, the two amino acids were significantly more effective than placebo at relieving depressive symptoms. The authors were direct that the evidence base is small, mostly old, and at risk of bias — which is still the honest summary in 2026. An older double-blind trial (Nardini et al., 1983, PMID 6381336) found 5-HTP at 300 mg/day combined with chlorimipramine produced significantly greater improvement on the Hamilton Rating Scale than chlorimipramine plus placebo over 28 days, supporting the substrate-supplementation rationale in a depressed population. More recent work by Tan et al. (2024, Clinical Nutrition / J Nutr Health Aging, PMC12430700) on 100 mg/day 5-HTP in older Singaporean adults reported a significant improvement in Montreal Cognitive Assessment scores versus baseline at 12 weeks.

For L-theanine, the evidence is younger and more consistent at the behavioral level. Hidese et al. (Nutrients, 2019, PMID 31623400) randomized 30 healthy adults to 200 mg/day L-theanine or placebo for four weeks and reported reduced stress-related symptoms and improved cognitive function (executive scores, verbal fluency) versus placebo. Kahathuduwa et al. (Sci Rep, 2020) showed that an L-theanine plus caffeine combination improved sustained attention and inhibitory control in a proof-of-concept neuroimaging RCT — important because the caffeine-plus-theanine literature is the closest established evidence model for the broader "pairing L-theanine with a co-active" hypothesis.

What this means for the MIHIYO Mood-Boost strip

The MIHIYO Labs Mood-Boost ODS is formulated around the calm-focus rationale described above: a low milligram dose of 5-HTP plus a study-aligned dose of L-theanine, delivered through the buccal/sublingual route as a thin polymer strip that dissolves in roughly 60–90 seconds. ODS, short for oral dissolving strip, is a thin polymer film that delivers active ingredient through the oral mucosa rather than down the GI tract.

I want to be careful about what this dosage form does and does not change. For L-theanine, the published oral PK is already excellent — Tmax around 50 minutes, high bioavailability — and the strip format is mainly a convenience and dose-precision choice rather than a bioavailability play. For 5-HTP, the molecule is well absorbed orally (~70 percent), and the buccal route may reduce some of the peripheral conversion problem discussed in the next section, but I do not have a published head-to-head PK study on a 5-HTP sublingual strip to cite. The honest framing is: the actives are chosen on mechanism and on published clinical work using the same molecules in other formats; the delivery format is chosen for dose precision and convenience. If you are evaluating the stack, evaluate the molecules first.

If you are reading this article in the context of a broader interest in dosage-form science, the related Caffeine ODS pillar covers why route of administration matters less for some molecules than people assume, and the Sleep-Support strip article covers the receptor-saturation logic behind low-dose precision dosing — both are relevant context for how I think about this category.

Where this approach has limits — and what I will not claim

Several things, stated plainly.

There is no published human RCT on the specific 5-HTP + L-theanine combination. I searched PubMed and the relevant systematic reviews through May 2026; the closest established pairing evidence is L-theanine + caffeine, which is mechanistically distinct. The case for the 5-HTP + L-theanine pair rests on the combined mechanism and the independent clinical work on each molecule. That is a reasonable formulation rationale; it is not the same as a positive head-to-head trial.

The peripheral conversion problem for 5-HTP is real. Aromatic L-amino acid decarboxylase is present in the gut wall, liver, and other peripheral tissues — not just the brain. A meaningful fraction of an oral 5-HTP dose is decarboxylated to serotonin in the periphery, where it does not contribute to mood effects and can cause nausea and GI side effects (Birdsall, 1998). In neurology, this is solved by co-administering carbidopa, a peripheral AADC inhibitor that does not cross the blood-brain barrier — the same trick used with levodopa in Parkinson's disease (Nardini et al., 1983). Carbidopa is a prescription drug, not a supplement ingredient. Supplement 5-HTP is taken without it, which means central serotonin elevation is less efficient than the rate-limiting-step story alone suggests.

Serotonin syndrome is a real interaction risk. 5-HTP should not be combined with prescription serotonergic medications — SSRIs, SNRIs, MAOIs, tramadol, certain triptans — without medical supervision. The risk is dose-related and well documented in pharmacology references.

L-theanine's effect size is modest. Published EEG alpha increases and stress-marker reductions are statistically significant but not large. Anyone expecting a sedative experience will be disappointed; the molecule shifts the dial, it does not flip a switch.

These studies were not run on MIHIYO products. Every citation in this article is on independent research using 5-HTP or L-theanine in capsule, drink, or solution form, not on the MIHIYO ODS. The mechanism is general; the specific PK profile of our strip would require a head-to-head trial we do not currently have.

The bottom line

The case for combining 5-HTP and L-theanine is built on coherent mechanism, not on a positive combination trial. 5-HTP supplies the substrate the brain uses to synthesize serotonin; L-theanine shifts cortical activity toward the calm-but-alert alpha state and modulates GABA and glutamate. Each has independent clinical evidence — older and small for 5-HTP, younger and more consistent for L-theanine. Neither molecule is a treatment for depression, anxiety, or any clinical condition; both are food-source amino-acid derivatives with measurable but modest effects in healthy adults. The right framing for 5-HTP and L-theanine is "two complementary mechanisms, dosed conservatively, used with awareness of the limits." Anything stronger than that is marketing.

References

1. Birdsall TC. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Alternative Medicine Review. 1998;3(4):271-280. PMID: 9727088. <https://pubmed.ncbi.nlm.nih.gov/9727088/>

1. Nakamura K, Hasegawa H. Production and Peripheral Roles of 5-HTP, a Precursor of Serotonin. International Journal of Tryptophan Research. 2009;2:37-43. PMCID: PMC3195225. <https://pmc.ncbi.nlm.nih.gov/articles/PMC3195225/>

1. Shaw K, Turner J, Del Mar C. Tryptophan and 5-Hydroxytryptophan for depression. Cochrane Database of Systematic Reviews. 2002;(1):CD003198. PMID: 11687048. <https://pubmed.ncbi.nlm.nih.gov/11687048/>

1. Nardini M, De Stefano R, Iannuccelli M, Borghesi R, Battistini N. Treatment of depression with L-5-hydroxytryptophan combined with chlorimipramine, a double-blind study. International Journal of Clinical Pharmacology Research. 1983;3(4):239-250. PMID: 6381336. <https://pubmed.ncbi.nlm.nih.gov/6381336/>

1. Tan ESS, Ho YB, Chan YM, Tan PY, Mahadzir MDA, Tan CK. The Impact of 5-Hydroxytryptophan Supplementation on Cognitive Function and Mood in Singapore Older Adults: A Randomized Controlled Trial. Nutrients / J Nutr Health Aging. 2024. PMCID: PMC12430700. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12430700/>

1. Nathan PJ, Lu K, Gray M, Oliver C. The neuropharmacology of L-theanine (N-ethyl-L-glutamine): a possible neuroprotective and cognitive enhancing agent. Journal of Herbal Pharmacotherapy. 2006;6(2):21-30. PMID: 17182482. <https://pubmed.ncbi.nlm.nih.gov/17182482/>

1. Nobre AC, Rao A, Owen GN. L-theanine, a natural constituent in tea, and its effect on mental state. Asia Pacific Journal of Clinical Nutrition. 2008;17 Suppl 1:167-168. PMID: 18296328. <https://pubmed.ncbi.nlm.nih.gov/18296328/>

1. Williams JL, Everett JM, D'Cunha NM, Sergi D, Georgousopoulou EN, Keegan RJ, McKune AJ, Mellor DD, Anstice N, Naumovski N. A Randomized, Triple-Blind, Placebo-Controlled, Crossover Study to Investigate the Efficacy of a Single Dose of AlphaWave L-Theanine on Stress in a Healthy Adult Population. Neurology and Therapy. 2021;10(2):1061-1078. PMCID: PMC8475422. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8475422/>

1. Hidese S, Ogawa S, Ota M, Ishida I, Yasukawa Z, Ozeki M, Kunugi H. Effects of L-Theanine Administration on Stress-Related Symptoms and Cognitive Functions in Healthy Adults: A Randomized Controlled Trial. Nutrients. 2019;11(10):2362. PMID: 31623400. <https://pubmed.ncbi.nlm.nih.gov/31623400/>

1. Kahathuduwa CN, Wakefield S, West BD, Blume J, Dassanayake TL, Weerasinghe VS, Mastergeorge A. Effects of L-theanine-caffeine combination on sustained attention and inhibitory control among children with ADHD: a proof-of-concept neuroimaging RCT. Scientific Reports. 2020;10(1):13072. <https://www.nature.com/articles/s41598-020-70037-7>